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Abstract
Introduction High body mass index has been associated with
increased risk for various cancers, including breast cancer. Here
we describe studies using 7,12-dimethylbenz(a)anthracene
(DMBA) to investigate the role of obesity in DMBA-induced
mammary tumor susceptibility in the female Zucker rat (fa/fa),
which is the most widely used rat model of genetic obesity.
Method Fifty-day-old female obese (n = 25) and lean (n = 28)
Zucker rats were orally gavaged with 65 mg/kg DMBA. Rats
were weighed and palpated twice weekly for detection of
mammary tumors. Rats were killed 139 days after DMBA
treatment.
Results The first mammary tumor was detected in the obese
group at 49 days after DMBA treatment, as compared with 86
days in the lean group (P < 0.001). The median tumor-free time
was significantly lower in the obese group (P < 0.001). Using
the days after DMBA treatment at which 25% of the rats had
developed mammary tumors as the marker of tumor latency, the
obese group had a significantly shorter latency period (66 days)
than did the lean group (118 days). At the end of the study,
obese rats had developed a significantly (P < 0.001) greater
mammary tumor incidence (68% versus 32%) compared with
the lean group. The tumor histology of the mammary tumors
revealed that obesity was associated with a significant (P <
0.05) increase in the number of rats with at least one invasive
ductal and lobular carcinoma compared with lean rats.
Conclusion Our results indicate that obesity increases the
susceptibility of female Zucker rats to DMBA-induced mammary
tumors, further supporting the hypothesis that obesity and some
of its mediators play a significant role in carcinogenesis.
Introduction
Obesity has been identified as an epidemic in the USA for
more than two decades, yet the proportion of overweight and
obese adults in the population continues to grow. The most
recent data from the 1999–2000 National Health and Nutri-
tion Examination Survey (NHANES) [1] showed that almost
65% of adults in the USA are overweight, defined as having a
body mass index (BMI) greater than 25 kg/m2. This is a signif-
icant increase from the 56% for adults reported as overweight
in NHANES III, which was conducted between 1988 and
1994. The prevalence of obesity, defined as a BMI of 30 kg/
m2 or greater, also increased dramatically from 23% to 31%
during the same period. It is estimated that the prevalence of
obesity in adults will rise to 39% by the year 2008. This trend
has alarming health and economic implications, because
obesity is associated with major causes of morbidity and mor-
tality such as diabetes, cardiovascular disease and several
types of cancers, including breast cancer [2,3]. Breast cancer
is the most common malignant tumor among women, being
the second leading killer of women in the USA [4]. Epidemio-
logical studies link breast cancer and obesity in postmenopau-
sal women [4-6]; almost half of breast cancer cases among
postmenopausal women occur in those with a BMI in excess
of 29 kg/m2 [7]. Although a number of studies have shown that
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excess weight is a risk factor for breast and other cancers,
Calle and coworkers [8] concluded that 20% of all deaths
from cancer in women aged over 50 years old could be attrib-
uted to being overweight or obese.
In experimental models, higher body weight has been associ-
ated with an increase in both spontaneous and chemically
induced mammary tumors in various strains of mice [7,9-12].
In order to understand better the mechanisms that are associ-
ated with obesity and cancer, we have turned our attention to
Zucker rats as a model. The Zucker rat (fa/fa) is the best
known, most widely used rat model of genetic obesity. Obesity
in the Zucker rat is inherited as an autosomal-recessive trait
caused by a mutation (fa) in the leptin receptor gene [13,14],
discovered by Zucker and Zucker [15,16]. Animals
homozygous for the fa allele become noticeably obese by age
3–5 weeks, and by 14 weeks of age more than 40% of their
body is composed of lipids [17]. Many investigators have used
this model to study the development, etiology, associated
pathogenesis, possible treatment, and putative mechanisms of
severe obesity [18]. Obese Zucker rats develop hyperinsuline-
mia and insulin resistance before they develop obesity-associ-
ated, non-insulin-dependent diabetes mellitus in a manner
similar to that in humans [19]. Lean Zucker rats, in contrast,
exhibit normal metabolic function and are considered ideal
controls. Consequently, this model is an ideal one in which to
investigate the relationship between obesity and mammary
tumor development.
There has been only one study published that used female
Zucker rats as a model to investigate the role of obesity in
mammary tumor development [20]. That study used N-methyl-
N-nitrosourea (MNU) as a carcinogen and reported that lean
rats developed more mammary tumors than did obese ones.
Because of its similarity to human breast cancer, researchers
have widely used the 7,12-dimethylbenz(a)anthracene
(DMBA)-induced rat mammary carcinoma model to investigate
breast carcinogenesis. In the present study we observed that
DMBA-induced mammary tumors in obese Zucker rats
develop faster than they do in lean counterparts, and that
obese animals were at more than double the risk for develop-
ing DMBA-induced mammary tumors. Therefore, our results
suggest that this model parallels the epidemiological data and
is an appropriate model in which to investigate the mecha-
nism(s) that underlie the role of obesity in mammary tumor
development and possible prevention strategies.
Materials and methods
Experimental design
All animal protocols were approved by the Institutional Animal
Care and Use Committee at the University of Arkansas for
Medical Sciences. Obese fa/fa (n = 25) and lean (n = 28)
Zucker rats were purchased at age 6 weeks (Harlan Indus-
tries, Indianapolis, IN, USA) and housed in the animal facilities
at the Arkansas Children's Hospital Research Institute. Rats
were housed two per cage in polycarbonate cages and
allowed free access to water and regular chow (Harlan-Teklad,
Madison, WI, USA). At the age of 50 days, all rats received via
gavage 65 mg/kg DMBA (Sigma Chemical Co., St. Louis, MO,
USA), a chemical procarcinogen used widely to produce
mammary adenocarcinoma in rats, in sesame oil [21,22]. Rats
were weighed twice per week. Beginning 2 weeks after
DMBA treatment, all rats were palpated twice weekly to detect
mammary tumors. The detection date and location of each
mammary tumor was recorded for each rat. Rats were killed
139 days after DMBA treatment. All mammary tumors were
excised, counted, and weighed. Rats with tumor masses
exceeding 2.5 cm in diameter were killed early for humane rea-
sons, in accordance with our Institutional Animal Care and Use
Committee-approved animal protocol. Sections of all tumors
were placed in 10% neutral buffered formalin for histopatho-
logic analysis. Sections (5 µm) of the paraffin-embedded
tumors were stained with hematoxylin and eosin for histologic
analysis.
Pathology
A board-certified anatomic pathologist (SK) evaluated tumors
in a blinded protocol and classified them as benign or intra-
ductal proliferation, as shown by multiple papillomas or with
ductal hyperplasia, ductal carcinoma in situ, or invasive ductal
and lobular carcinoma.
Statistical analysis
A one-way analysis of variance [23] was used to analyze body
weight following DMBA treatment. The tumor-free times were
plotted using a Kaplan–Meier curve [24] and the median times
were compared using a generalized Wilcoxon test [25]. When
there is no censoring, this test is equivalent to a Mann–Whit-
ney rank sum test. Fisher's exact test [26] was used to com-
pare the percentage of rats with tumors and tumor histology in
each group. The median numbers of tumors per tumor-bearing
rat (multiplicity) for each group were compared using the non-
parametric Mann–Whitney test [27]. Statistical significance
was set at P < 0.05, and all P values were unadjusted for mul-
tiple comparisons. For the few rats that were killed early
because of tumor burden, we assumed that the number of
tumors remained constant until the end of the study. Data anal-
yses were generated and plots were constructed using
SPSS© version 12.0 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
Body and organ weights
As expected, all rats gained weight during the course of the
experiment. The average body weights (mean ± standard
error) are shown in Fig. 1a. Obese rats gained significantly (P
< 0.001) more weight than did lean rats. At the beginning of
the study (7 days before DMBA treatment) the mean body
weights of lean and obese rats were 102.5 ± 1.5 g and 148 ±
3.5 g, respectively. At the end of the study, the final mean bodyAvailable online http://breast-cancer-research.com/content/7/5/R627
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weights for lean and obese rats were 262.3 ± 4.2 g and 517.2
± 17.9 g, respectively. The obese rats gained approximately
twice the weight of the lean rats. Obesity was associated with
a significant increase in liver (P < 0.001) and kidney (P <
0.001) weights compared with those in the lean group (Table
1). This increase in liver weight in obese rats also was evident
when liver weight was expressed as percentage of body
weight (P < 0.001); however, kidney weight as a percentage
of body weight was not affected significantly by obesity.
Time course for tumor formation, latency and multiplicity
The time course of palpable mammary tumor detection is
shown in Fig. 1b, and data are presented in Table 2. The tumor
latency (the number of days after DMBA treatment until detec-
tion of the first mammary tumor) was shorter in obese rats than
in the lean rats. The first mammary tumor detected in obese
rats was 49 days after DMBA treatment versus 86 days in lean
rats, which represents a significant 37-day delay for the devel-
opment of mammary tumors in lean rats (Table 2). In addition,
it took only 66 days after DMBA treatment for 25% of the
obese rats to develop mammary tumors versus 118 days in
lean rats – a delay of 52 days. The median tumor-free time was
significantly lower in the obese group (P < 0.001; Fig. 1b). By
the end of the study (139 days after DMBA treatment), 68%
of obese rats had developed mammary tumors as compared
with only 32% of the lean rats (P  < 0.001; Fig. 1b). The
median number of mammary tumors per tumor-bearing rat
(multiplicity) increased from one tumor per rat in the lean group
(range: one to four tumors per rat) to two tumors per rat in the
obese group (range: one to four tumors per rat; Table 2).
For further comparison of mammary tumor development we
evaluated tumor multiplicity at three time points (70, 105 and
139 days after DMBA treatment). As demonstrated in Fig. 1c,
the obese rats developed mammary tumors earlier than did
lean rats. At 70 days after DMBA treatment, several rats in the
obese group had one to three tumors each, whereas no mam-
mary tumors were detected in the lean group. At 105 days
after DMBA treatment there were several rats in the obese
group with tumors, including five rats with one tumor each, four
rats with two tumors, two rats with three tumors, and one rat
with four tumors. This is in contrast to the lean group, in which
only three rats had one tumor each and one rat had two
tumors. At 139 days after DMBA treatment, there were seven
rats in obese group with one tumor each, three rats with two
tumors, four rats with three tumors, and three rats with four
tumors. In contrast, the lean group had five rats with one tumor
each, two rats with two tumors, one rat with three tumors, and
one rat with four tumors. These findings indicate for the first
time that obese Zucker rats are an excellent model for investi-
gating the role of obesity in DMBA-induced mammary tumor
development.
Mammary tumor characteristics
Mammary tumor histology data and morphology are presented
in Table 2 and Fig. 2, respectively. Nine rats (32%) in the lean
group developed mammary tumors compared with 17 rats
(68%) in the obese group. Only two rats (7%) in the lean
group had at least one tumor graded as intraductal prolifera-
tion compared with four rats (16%) in the obese group. Five
rats (19%) in the lean group had at least one tumor graded as
Figure 1
Body weights and mammary tumor incidence and multiplicity in DMBA- treated Zucker rats Body weights and mammary tumor incidence and multiplicity in DMBA-
treated Zucker rats. (a) Body weights of lean and obese female rats. 
(b) Mammary tumor incidence (percentage of rats with tumors) in 
female rats. Dashed lines indicate the post-DMBA (7,12-dimethyl-
benz(a)anthracene) days at which 25% of the obese and lean rats 
developed at least one mammary tumor. (c) Mammary tumor multiplicity 
in obese and lean rats.Breast Cancer Research    Vol 7 No 5    Hakkak et al.
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ductal carcinoma in situ, compared with six rats (24%) in the
obese group. Obesity significantly increased (P < 0.05) the
number of rats (7 rats, 28%) with at least one tumor graded as
invasive ductal and lobular carcinoma compared with the lean
group (2 rats, 7%). A total of 53 mammary tumors were
detected in the study; 37 tumors (70% of the total tumors)
were detected in the obese group versus 16 tumors (30% of
the total tumors) in the lean group. Obesity was associated
with a nonsignificant increase in tumor weight.
Discussion
Higher body weight is associated with increased incidence of
both spontaneous and chemically induced mammary tumors in
various strains of mice [9,10,12,28]. For example, the Leprdb
and Lepob-TGFα  transgenic mouse model, used to investigate
the effects of obesity on tumorigenesis, are leptin deficient or
have a leptin receptor defect. However, these mice do not
develop mammary tumors and therefore are not a suitable
model in which to study the role of obesity in breast cancer
Table 1
Organ weights of lean and obese female zucker rats
Organ Lean (n = 28) Obese (n = 25)
Liver
Absolute 8.10 ± 0.14 22.08 ± 0.72**
Relative 3.05 ± 0.038 4.38 ± 0.12**
Kidney
Absolute 1.62 ± 0.35 2.95 ± 0.10**
Relative 0.61 ± 0.01 0.59 ± 0.02
Organ weights (absolute weights) are given in grams; organ weight to body weight ratios are given as grams organ weight/grams body weight as 
a percentage (mean ± standard error). **P < 0.001 versus the lean group (Fisher's exact test).
Table 2
Characteristics of DMBA-induced mammary tumors in lean and obese female Zucker rats
Characteristic Lean (n = 28) Obese (n = 25)
Tumor onset
Day of first tumora 86 49**
Day at 25% tumorsb 118 66**
Pc 0.001
Tumor incidence
% of rats with tumorsd 32 68**
Pe 0.001
Multiplicityf 1 (1–4) 2 (1–4)
Pc 0.42
Tumor weight (g)g 0.37 (0.01–6.44) 0.42 (0.05–7.70)
Pc 0.47
Rats with tumorsh
IDP 2 (7%) 4 (16%)
DCIS 5 (19%) 6 (24%)
IDC 2(7%) 7 (28%)*
aPost-DMBA (7,12-dimethylbenz(a)anthracene) day at which the first mammary tumor was detectable by palpation. bPost-DMBA day at which the 
probability of tumor development was 25%. cP values based on generalized Wilcoxon test. dPercentage of rats with at least one mammary tumor. 
eP values based on the Fisher's exact test. fMedian number of tumors in tumor bearing rats (minimum-maximum in parentheses). gMedian tumor 
weight (minimum-maximum in parentheses). hNumber and percentage of rats with at least one tumor graded as intraductal proliferation (IDP), 
ductal carcinoma in situ (DCIS), or invasive ductal and lobular carcinoma (IDC), as described in the Materials and method section. **P < 0.001, 
*P < 0.05.Available online http://breast-cancer-research.com/content/7/5/R627
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[29]. In the present study we observed that obese Zucker rats
are more susceptible to DMBA-induced tumorigenesis than
are lean rats. These data clearly demonstrate the following
when DMBA was administered as a carcinogen to female
Zucker rats: obese rats developed mammary tumors at a faster
rate than did lean rats; obese rats exhibited shorter latency
periods, both at the time of appearance of the first tumor and
at the day at which tumor incidence reached 25%, than lean
did rats; obesity resulted in a greater incidence of mammary
tumors; obese rats developed significantly more invasive duc-
tal and lobular carcinoma than did lean rats; and obese rats
had a higher tumor multiplicity, albeit not statistically signifi-
cantly so, compared with lean rats.
Using Sprague–Dawley female rats, Klurfeld and colleagues
[30] studied the effects of calorie restriction on mammary
tumor induction by DMBA in rats fed a high-fat diet. They
found that a 25% calorie restriction resulted in a significant
reduction in mammary tumor incidence and tumor weight in
both control rats and rats fed a high-fat diet. Further experi-
ments implicated decreased serum insulin and insulin-like
growth factor I levels in the inhibition of mammary tumor pro-
motion in calorie restricted rats [31].
In agreement with the present data in female Zucker rats,
genetically obese LA/N-cp (corpulent) female rats developed
more mammary tumors than did phenotypically lean littermates
when they were treated with DMBA. Klurfeld and coworkers
[28] reported that calorie restriction (40%) reduced tumor
incidence to 27%, compared with the 100% tumor incidence
observed in obese animals fed ad libitum. Those investigators
suggested that calorie restriction resulted in decreased insulin
levels, implicating hyperinsulinemia in obese ad libitum fed
rats as a mechanism in increased tumor promotion.
The number of overweight and obese Americans has doubled
in the past two decades, which may have an impact on cancer
risk and survival [1]. The association between obesity and
breast cancer risk has been inconclusive in a number of epide-
miologic studies. Several studies have reported that increased
body mass in premenopausal women is not associated with
increased risk for breast cancer, whereas the same studies
have demonstrated a positive association between increased
body mass and breast cancer risk in postmenopausal women
[32,33]. Recent epidemiologic studies have suggested that
the age at which a woman gains weight may be a more rele-
vant factor in determining breast cancer risk [34].
Our results are in contrast to those of a previous study, which
used MNU as a carcinogen to induce mammary tumors. In that
study [20] the authors reported that lean and obese rats had
developed tumors at the same rate at 29 weeks after MNU
treatment. However, 50% of the lean rats developed carcino-
mas of the mammary gland, as compared with only 10% of the
obese rats. Also, they reported a higher incidence of colorectal
tumors in obese rats than in lean rats. Although MNU and
DMBA both produce mammary tumors in female rats, these
tumors arise by different mechanisms of action [35]. MNU is a
direct acting carcinogen and does not require metabolic acti-
vation in order to form adducts that damage DNA [36,37].
DMBA is a procarcinogen that requires metabolic activation by
cytochrome P450 enzymes to reactive metabolites (dihydrodi-
olepoxides) that can form mutagenic DNA adducts [35].
These reactions are catalyzed principally by CYP1A2 in the
liver and CYP1A1 and CYP1B1 in peripheral tissues such as
the mammary gland.
Our findings are consistent with those reported for induction
of colon cancer with azoxymethane in mature, genetically
Figure 2
Mammary tumor histology Mammary tumor histology. (a) Intraductal proliferation (intraductal papil-
loma). Original magnification: 40×. (b) Higher magnification of panel a. 
Original magnification 200×. (c) Ductal carcinoma in situ. Original 
magnification: 40×. (d) Higher magnification shows proliferation of uni-
form neoplastic cells with high nucleus to cytoplasmic ratio within duc-
tal structures. Original magnification: 200×. (e) Invasive ductal 
carcinoma; arrow shows tumor necrosis in lower left corner. Original 
magnification: 40×. (f) Higher magnification shows neoplastic cells dif-
fusely infiltrating the stroma. Original magnification: 200×.Breast Cancer Research    Vol 7 No 5    Hakkak et al.
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obese male Zucker rats. In that study [38] obese Zucker rats
had significantly more colonic aberrant crypt formation than
did any of the lean rats. Although the mechanism for an asso-
ciation with colon carcinogenesis is unknown, it is hypothe-
sized that insulin and leptin resistance may play a role because
leptin levels are typically threefold higher in the genetically
obese Zucker (fa/fa) rats than in their lean counterparts,
because of the leptin receptor defect in these animals [39].
However, recent results from epidemiological studies do not
support the hypothesis that plasma leptin is a risk factor for
breast cancer [40]. Nevertheless, body composition and
weight are considered breast cancer risk factors that may
influence prognosis [41].
The relevance of DMBA is that humans are exposed to DMBA
and other polycyclic aromatic hydrocarbons through environ-
mental or dietary sources, which may function in a synergistic
manner with obesity and breast carcinogenesis. Exposure to
polycyclic aromatic hydrocarbons in meats cooked at high
temperature has been implicated in the development of breast
cancer [42,43]. We have demonstrated that obesity increases
the susceptibility of female Zucker rats to development of
mammary tumors when DMBA is used as the inducing carcin-
ogen. The mechanisms responsible for the observed
increased risk for developing mammary tumors with obesity
are not clearly understood. Several mechanisms may play
roles in explaining the relationship we observed between
obesity and increased mammary tumor development, includ-
ing adipose associated hormones, adipokines, and inflamma-
tion [44], which are manifested by the general genetics of the
animals; the exact relationships remain undefined and further
work is needed. Future experiments with this model will focus
on delineating the mechanisms responsible for this increased
susceptibility to mammary cancer.
Conclusion
In conclusion, we have demonstrated that obesity increases
the susceptibility of female Zucker rats to development of
mammary tumors when DMBA is used as the inducing carcin-
ogen. The mechanisms responsible for the observed
increased risk for developing mammary tumors with obesity
remain to be defined.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
RH applied for and received funding for this project, designed
and supervised the study, and participated in collection of
tumor data and writing of the manuscript. AH coordinated and
carried out the daily activities regarding overseeing the ani-
mals, recording data, and processing the samples. SM partic-
ipated in the study design, interpretation of the results, and
drafting of the manuscript. PS and CHJ participated in the
study design and performed the statistical analyses. GF partic-
ipated in the study design. TK-E contributed to the study
design, analysis and interpretation of the results, and writing of
the manuscript. SK provided expertise in classifying and ana-
lyzing all of the mammary tumors and participated in
interpretation of study results and writing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the University of Arkansas for Medical Sci-
ences Children's University Medical Group and Arkansas Cancer 
Research Center Breast Cancer Program and the Arkansas Bioscience 
Institute, the major research component of the Tobacco Settlement Pro-
ceeds Act of 2000. The authors wish to thank Phaedra Yount for valua-
ble assistance in preparing the manuscript.
References
1. National Center for Health Statistics: National Health and Nutri-
tion Examination Survey.  [http://www.cdc.gov/nchs/
nhanes.htm].
2. Anonymous: NHLBI Obesity Education Initiative Expert Panel.
Obes Res 1998, 6:51S.
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS,
Marks JS: Prevalence of obesity, diabetes, and obesity-related
health risk factors, 2001. JAMA 2003, 289:76-79.
4. Cleary MP, Maihle NJ: The role of body mass index in the rela-
tive risk of developing premenopausal versus postmenopau-
sal breast cancer. Proc Soc Exp Biol Med 1997, 216:28-43.
5. Willett WC: Fat, energy and breast cancer.  J Nutr 1997,
127:921S-923S.
6. Galanis DJ, Kolonel LN, Lee J, Le Marchand L: Anthropometric
predictors of breast cancer incidence and survival in a multi-
ethnic cohort of female residents of Hawaii, United States.
Cancer Causes Control 1998, 9:217-224.
7. Ballard-Barbash R, Swanson CA: Body weight: estimation of
risk for breast and endometrial cancers. Am J Clin Nutr 1996,
63:437S-441S.
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Over-
weight, obesity, and mortality from cancer in a prospectively
studied cohort of U.S. adults.  N Engl J Med 2003,
348:1625-1638.
9. Waxler SH, Tabar P, Melcher LR: Obesity and the time of
appearance of spontaneous mammary carcinoma in C3H
mice. Cancer Res 1953, 13:276-278.
10. Waxler S: Obesity and cancer susceptibility in mice. Am J Clin
Nutr 1960, 8:760-766.
11. Haseman JK, Bourbina J, Eustis SL: Effect of individual housing
and other experimental design factors on tumor incidence in
B6C3F1 mice. Fundam Appl Toxicol 1994, 23:44-52.
12. Wolff GL, Kodell RL, Cameron AM, Medina D: Accelerated
appearance of chemically induced mammary carcinomas in
obese yellow (Avy/A) (BALB/c X VY) F1 hybrid mice. J Toxicol
Environ Health 1982, 10:131-142.
13. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R,
Richards GJ, Campfield LA, Clark FT, Deeds J, et al.: Identifica-
tion and expression cloning of a leptin receptor, OB-R. Cell
1995, 83:1263-1271.
14. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia
L, Leibel RL: Phenotypes of mouse diabetes and rat fatty due
to mutations in the OB (leptin) receptor.  Science 1996,
271:994-996.
15. Zucker L, Zucker TF: Fatty, a new mutation in the rat. J Heredity
1961, 52:275-278.
16. Zucker TF, Zucker LM: Fat accretion and growth in the rat. J Nutr
1963, 80:6-19.
17. Zucker LM: Fat mobilization in vitro and in vivo in the geneti-
cally obese Zucker rat 'fatty'. J Lipid Res 1972, 13:234-243.
18. Bray GA, York DA, Fisler JS: Experimental obesity: a homeo-
static failure due to defective nutrient stimulation of the sym-
pathetic nervous system. Vitam Horm 1989, 45:1-125.
19. Bray GA: The Zucker-fatty rat: a review.  Fed Proc 1977,
36:148-153.Available online http://breast-cancer-research.com/content/7/5/R627
R633
20. Lee WM, Lu S, Medline A, Archer MC: Susceptibility of lean and
obese Zucker rats to tumorigenesis induced by N-methyl-N-
nitrosourea. Cancer Lett 2001, 162:155-160.
21. Hakkak R, Korourian S, Shelnutt SR, Lensing S, Ronis MJ, Badger
TM: Diets containing whey proteins or soy protein isolate pro-
tect against 7,12-dimethylbenz(a)anthracene-induced mam-
mary tumors in female rats. Cancer Epidemiol Biomarkers Prev
2000, 9:113-117.
22. Hakkak R, Kourourian S, Fletcher T, Hale J, Fergusonn M, Ronis M,
Badger T: The effects of rice protein isolate on DMBA-induced
mammary tumors in rats. Proc Am Assoc Cancer Res 2002,
48:823.
23. Altman DG: Practical Statistics for Medical Research London:
Chapman and Hall; 1991. 
24. Cox DR, Oakes D: Analysis of Survival Data London: Chapman
and Hall; 1984. 
25. Gross AJ, Clark VA: Survival Distribution: Reliability Applications
in Biomedical Sciences New York: Wiley; 1975. 
26. Bhattacharyya GK, Johnson RA: Statistical Concepts and
Methods New York: Wiley; 1977. 
27. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance
analysis. J Am Stat Assoc 1952, 47:583-621.
28. Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky
D: Reduction of enhanced mammary carcinogenesis in LA/N-
cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med
1991, 196:381-384.
29. Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin: a growth factor in
normal and malignant breast cells and for normal mammary
gland development. J Natl Cancer Inst 2002, 94:1704-1711.
30. Klurfeld DM, Welch CB, Lloyd LM, Kritchevsky D: Inhibition of
DMBA-induced mammary tumorigenesis by caloric restriction
in rats fed high-fat diets. Int J Cancer 1989, 43:922-925.
31. Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW: Caloric
restriction and 7,12-dimethylbenz(a)anthracene-induced
mammary tumor growth in rats: alterations in circulating insu-
lin, insulin-like growth factors I and II, and epidermal growth
factor. Cancer Res 1989, 49:4130-4134.
32. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard
B, Berrino F, Tjonneland A, Bigaard J, Olsen A, et al.: Body size
and breast cancer risk: findings from the European Prospec-
tive Investigation into Cancer And Nutrition (EPIC). Int J Cancer
2004, 111:762-771.
33. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson
L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, et al.:
Pooled analysis of prospective cohort studies on height,
weight, and breast cancer risk.  Am J Epidemiol 2000,
152:514-527.
34. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L,
Lopez AM, Manson J, Margolis KL, Muti PC, et al.: Obesity, body
size, and risk of postmenopausal breast cancer: the Women's
Health Initiative (United States). Cancer Causes Control 2002,
13:741-751.
35. Rowlands JC, He L, Hakkak R, Ronis MJ, Badger TM: Soy and
whey proteins downregulate DMBA-induced liver and mam-
mary gland CYP1 expression in female rats.  J Nutr 2001,
131:3281-3287.
36. Russo J, Russo IH: Experimentally induced mammary tumors in
rats. Breast Cancer Res Treat 1996, 39:7-20.
37. Russo IH, Russo J: Mammary gland neoplasia in long-term
rodent studies. Environ Health Perspect 1996, 104:938-967.
38. Weber RV, Stein DE, Scholes J, Kral JG: Obesity potentiates
AOM-induced colon cancer. Dig Dis Sci 2000, 45:890-895.
39. White BD, Martin RJ: Evidence for a central mechanism of
obesity in the Zucker rat: role of neuropeptide Y and leptin.
Proc Soc Exp Biol Med 1997, 214:222-232.
40. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R,
Olsson T: Plasma leptin and breast cancer risk: a prospective
study in northern Sweden.  Breast Cancer Res Treat 2004,
86:191-196.
41. Enger SM, Greif JM, Polikoff J, Press M: Body weight correlates
with mortality in early-stage breast cancer. Arch Surg 2004,
139:954-960.
42. Li D, Wang M, Dhingra K, Hittelman WN: Aromatic DNA adducts
in adjacent tissues of breast cancer patients: clues to breast
cancer etiology. Cancer Res 1996, 56:287-293.
43. Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W,
Grumet S, Perera FP: The relationship between genetic dam-
age from polycyclic aromatic hydrocarbons in breast tissue
and breast cancer. Carcinogenesis 2000, 21:1281-1289.
44. Trayhurn P, Wood IS: Adipokines: Inflammation and the pleio-
tropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.